Neil A Holtzman. Show Affiliations »
Abstract
Mesh: See more » Cost-Benefit AnalysisDisease ProgressionHumansInfant, NewbornMass SpectrometryMetabolism, Inborn Errors/diagnosisMetabolism, Inborn Errors/therapyNeonatal Screening/economicsNeonatal Screening/standardsReproducibility of ResultsRisk Assessment
Year: 2003 PMID: 14625339 DOI: 10.1001/jama.290.19.2606
Source DB: PubMed Journal: JAMA ISSN: 0098-7484 Impact factor: 56.272